Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Fortnite Crew Pack August 2023 Revealed
Music publishers sue Twitter for allowing copyrighted songs
Sony unveils new handheld streaming console, Project Q
British chip champion Arm files to go public in US
Kai Cenat unveils trailer for debut film inspired by 'Rush Hour' starring his Japanese friend Ray, psyched fans call it 'sick'
Paper Mario: The Thousand-Year Door Remaster Release Date
Need a New Look? How to Change Your iPhone Wallpaper
Twitter now publicly shows who you're paying to subscribe to via Subscriptions